stoxline Quote Chart Rank Option Currency Glossary
  
Vincerx Pharma, Inc. (VINC)
1.3  0.02 (1.56%)    02-14 16:00
Open: 1.29
High: 1.33
Volume: 72,494
  
Pre. Close: 1.28
Low: 1.29
Market Cap: 3(M)
Technical analysis
2025-02-14 4:52:18 PM
Short term     
Mid term     
Targets 6-month :  3.47 1-year :  4.76
Resists First :  2.97 Second :  4.07
Pivot price 1.46
Supports First :  1.17 Second :  0.98
MAs MA(5) :  1.31 MA(20) :  1.74
MA(100) :  5.78 MA(250) :  23.85
MACD MACD :  -0.7 Signal :  -0.7
%K %D K(14,3) :  8.2 D(3) :  5.1
RSI RSI(14): 29.8
52-week High :  187.44 Low :  1.17
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VINC ] has closed above bottom band by 26.7%. Bollinger Bands are 78.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.33 - 1.34 1.34 - 1.34
Low: 1.27 - 1.28 1.28 - 1.29
Close: 1.29 - 1.3 1.3 - 1.31
Company Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Headline News

Wed, 12 Feb 2025
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com

Fri, 31 Jan 2025
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat

Wed, 29 Jan 2025
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire

Mon, 27 Jan 2025
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq

Thu, 23 Jan 2025
Vincerx Pharma Inc. Announces Merger with Oqory - TipRanks

Thu, 23 Jan 2025
Vincerx Pharma Announces 1-for-20 Reverse Stock Split, Shares to Adjust January 28 - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 27 (M)
Held by Insiders 11.5 (%)
Held by Institutions 18.6 (%)
Shares Short 56 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS -17.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.43
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -83.3 %
Return on Equity (ttm) -211.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -12.24
Qtrly Earnings Growth 0 %
Operating Cash Flow -28 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.08
PEG Ratio 0
Price to Book value 3.02
Price to Sales 0
Price to Cash Flow -0.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android